When a nerve impulse arrives at a 5-HT or noradrenaline nerve terminal the neurotransmitter is released from the synaptic vesicle into the synaptic cleft. Neurotransmitter molecules bind to their specific receptors on the post-synaptic membrane and the nerve impulse is propagated or inhibited, depending on the receptor type. 5-HT and noradrenaline molecules are then released from their receptors and taken back into the nerve terminal via either the 5-HT or noradrenaline re-uptake transporters. 5-HT and noradrenaline are degraded by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), these enzymes are found in the nerve terminal.1,2
Click here: Learn about the normal processes of serotonin and noradrenaline synaptic activity
Related content
Fear, rejection, and “othering” of people living with epilepsy continues to be a major additional burden, a burden beyond seizures, for many people globally.
The complex interplay between metabolic dysfunction and brain insulin resistance in schizophrenia warrants further investigation as it represents a unique opportunity for both mechanistic inquiry and the development of novel therapeutic strategies that can improve metabolic and cognitive outcomes in this population.
Central and peripheral causes of brain insulin resistance in schizophrenia